88475-69-8

Basic information

• Product Name: Beraprost sodium
• Synonyms: beraprostsodium;ML 1129;PROCYLIN;TRK 100;BERAPROST SODIUM SALT;2,3,3A-8B-TETRAHYDRO-2-HYDROXY-1-(3-HYDROXY-4-METHYL-1-OCTEN-6-YNYL)-1H-CYCLOPENTA[B]BENZOFURAN-5-BUTANOIC ACID, SODIUM SALT;1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-, monosodium salt;Dorner
• CAS NO: 88475-69-8
• Molecular Formula: C₂₄H₃₀O₅
• Molecular Weight: 420.47
• Product Categories: Prostaglandins;Prostaglandin;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 88475-69-8.mol
• Article Data: 5

Chemical Properties

• Melting Point: 204-206°C
• Boiling Point: 572.1 °C at 760 mmHg
• Flash Point: 193.1 °C
• Appearance: white solid
• Vapor Pressure: 6.32E-14mmHg at 25°C
• Storage Temp.: Amber Vial, -20?C Freezer, Under Inert Atmosphere
• CAS DataBase Reference: Beraprost sodium(CAS DataBase Reference)
• NIST Chemistry Reference: Beraprost sodium(88475-69-8)
• EPA Substance Registry System: Beraprost sodium(88475-69-8)

Safety Data

• Hazardous Substances Data: 88475-69-8(Hazardous Substances Data)

Usage

Description

Different sources of media describe the Description of 88475-69-8 differently. You can refer to the following data:
1. Beraprost sodium is a new, orally active antithrombotic epoprostenol analog introduced as a treatment for peripheral vascular disease, including Raynaud's syndrome and Buerger's disease. The antiplatelet activity may be due to its elevation of cyclic AMP in platelets which is achieved by activating adenylate cyclase in the platelet membrane, followed by the inhibition ofCa++- influx and thromboxane A2 formation.
2. Beraprost is an analog of prostacyclin in which the unstable enol-ether has been replaced by a benzofuran ether function. This modification increases the plasma half-life from 30 seconds to several hours, and permits the compound to be taken orally. Doses of 20-100 μg in humans, given 1 to 3 times per day, have been demonstrated to improve clinical end points in diseases responsive to prostacyclin. Oral beraprost therapy improved the survival and pulmonary hemodynamics of patients with primary pulmonary hypertension. Beraprost inhibits platelet aggregation in healthy subjects and in diabetic patients at similar doses.

Chemical Properties

White Solid

Originator

Toray (Japan)

Brand name

Dorner; Dorner;Procylin

General Description

Beraprost sodium is an orally active prostacyclin analog.

Biochem/physiol Actions

Beraprost sodium is used as a therapeutic agent for chronic artery obstructions or primary pulmonary hypertension. In individuals with coronary artery disease, beraprost sodium helps to reduce oxidative stress and developed forearm endothelium dependent vasodilation.

InChI:InChI=1/C24H30O5.Na/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28;/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28);/q;+1/p-1/b13-12+;/t15?,17-,19+,20+,21-,23-;/m0./s1

Upstream product

• 88277-23-0 4-((1R,2R,3aS,8bS)-2-Acetoxy-1-formyl-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan-5-yl)-butyric acid methyl ester 
• 70073-58-4 dimethyl (2-oxo-3-methylhept-5-ynyl)-phosphonate 
• 474070-68-3 C₁₇H₂₀O₅ 
• 88295-11-8 4-((1S,2R,3aS,8bS)-2-Acetoxy-1-hydroxymethyl-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan-5-yl)-butyric acid methyl ester 
• 88277-19-4 methyl 4-((1S,2R,3aS,8bS)-2-hydroxy-1-(hydroxymethyl)-2,3,3a,8b-tetrahydro-1Hbenzo[b]cyclopenta[d]furan-5-yl)butanoate 

Relevant articles and documents

Synthetic method of beraprost

The invention relates to a synthetic method of beraprost. The synthetic method comprises the following steps: with an intermediate I as an initial raw material, carrying out selective primary alcoholoxidation and a Witting reaction to obtain an intermediate V; carrying out reduction and column chromatography purification on the intermediate V to obtain an intermediate IV; and hydrolyzing the intermediate IV to obtain beraprost. According to the synthetic method disclosed by the invention, two hydroxyl groups of the intermediate I are selectively oxidized, so a hydroxyl protection reagent is prevented from being used; in the oxidation step, ultralow-temperature (-60 to -80 DEG C) reactions and use of a reagent DCC with relatively high toxicity are avoided; in the reduction step, diisobutylaluminum hydride is prevented from being used; process operation units are greatly reduced, reaction steps are shortened, emission of three wastes is reduced, and the reactions are more efficient andenvironment-friendlier; and the main peak content of the prepared beraprost reaches 99.0% or above, and total process yield reaches 26% or above. The invention provides the synthetic method which ismore beneficial for industrial production.

ANTIHYPERTENSIVE THERAPY

A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.

USE OF SUBSTITUTED 2 PHENYLBENZIMIDAZOLES AS MEDICAMENTS

The present invention relates to the use of a substituted 2-phenylbenzimidazole of formula I wherein R1, R2, R3, R 4, R5 and m have the meanings given in the claims, for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors, as well as new compounds of formula I wherein R1 is a group of formula